BioRestorative Therapies (BRTX) Change in Account Payables (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Change in Account Payables came in at $482455.0 in Q4 2025, up 490.59% YoY from $81690.0 in Q4 2024, and up 109.57% on a QoQ basis from $230209.0 in Q3 2025.
BioRestorative Therapies (BRTX) Change in Account Payables (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Change in Account Payables data on file, last reported at $482455.0 in Q4 2025.
- Quarterly Change in Account Payables rose 490.59% year-over-year to $482455.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $839525.0 (up 185.86% YoY) and the FY2025 annual result came in at $839525.0, up 185.86% from the prior year.
- Change in Account Payables improved to $482455.0 in Q4 2025, from $230209.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $482455.0 in Q4 2025 to a low of -$297599.0 in Q4 2022.
- A 5-year average of $60187.2 and a median of $61601.5 in 2024 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2021 — Change in Account Payables plunged 362.59% — and 2025, when it surged 490.59%.
- Tracing BRTX's Change in Account Payables over 5 years: stood at -$73731.0 in 2021, then sank by 303.63% to -$297599.0 in 2022, then soared by 87.24% to -$37966.0 in 2023, then surged by 315.17% to $81690.0 in 2024, then surged by 490.59% to $482455.0 in 2025.
- The last three Change in Account Payables figures came in at $482455.0 (Q4 2025), $230209.0 (Q3 2025), and $10430.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | BioRestorative Therapies | 1.94 Mn | -1.02 Mn | 17,964.00 | 482,455.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 482,455.00 |
| Dec 31, 2025 | 482,455.00 |
| Sep 30, 2025 | 230,209.00 |
| Sep 30, 2025 | 230,209.00 |
| Jun 30, 2025 | 10,430.00 |
| Jun 30, 2025 | 10,430.00 |
| Mar 31, 2025 | 116,431.00 |
| Mar 31, 2025 | 116,431.00 |
| Dec 31, 2024 | 81,690.00 |
| Dec 31, 2024 | 81,690.00 |
| Sep 30, 2024 | 185,459.00 |
| Sep 30, 2024 | 185,459.00 |
| Jun 30, 2024 | -14,982.00 |
| Jun 30, 2024 | -14,982.00 |
| Mar 31, 2024 | 41,513.00 |
| Mar 31, 2024 | 41,513.00 |
| Dec 31, 2023 | -37,966.00 |
| Dec 31, 2023 | -37,966.00 |
| Sep 30, 2023 | -48,693.00 |
| Sep 30, 2023 | -48,693.00 |